Thymosin Beta-4 Fragment 17-23

Thymosin Beta-4 Fragment 17-23 (TB-500 Fragment 17-23)

1. Basic Overview

Thymosin Beta-4 Fragment 17–23 (commonly known as TB-500) is a synthetic acetylated heptapeptide. It corresponds to amino acid residues 17–23 of endogenous full-length Thymosin Beta-4 (Tβ4).

• Amino Acid Sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH (Ac-LKKTETQ)
• CAS Number: 885340-08-9
• Molecular Weight: 889.01 Da
• Form: Lyophilized white crystalline powder
• Core Feature: This short fragment contains the actin-binding domain, the primary functional motif responsible for most of Tβ4’s tissue regeneration activity. It is easier to synthesize, purify and cost-effective compared to full-length Thymosin Beta-4.
• Note: It is not naturally produced in the human body; it is a synthetic truncated peptide developed for research.

2. Mechanism of Action

1. High-affinity binding to monomeric globular actin (G-actin), regulating actin polymerization and cytoskeleton remodeling.
2. Promotes keratinocyte, fibroblast and endothelial cell migration, a critical step for wound closure and tissue regeneration.
3. Stimulates angiogenesis (new blood vessel formation) at injury sites to improve nutrient supply for damaged tissue.
4. Modulates local inflammatory response, reduces excessive inflammatory cell infiltration and limits pathological scar tissue formation.
5. Facilitates recruitment of progenitor/stem cells to damaged regions to accelerate musculoskeletal and soft tissue repair.

3. Main Research Applications

• Soft tissue wound healing, acute & chronic skin injury models
• Tendon, ligament and skeletal muscle damage regeneration research
• Angiogenesis and vascular tissue repair studies
• Anti-scarring and extracellular matrix remodeling experiments
• Ocular epithelial wound recovery research
• Comparative pharmacology: Full-length Tβ4 vs bioactive fragment screening
• Combined therapy research with regenerative peptides (BPC-157, GHK-Cu)

4. Reconstitution Instructions (Lyophilized Vial)

Common specification: 5mg / 10mg per vial

1. Let peptide vial reach room temperature; disinfect rubber stopper with alcohol.
2. Slowly inject Bacteriostatic Water along the inner glass wall. Avoid direct impact onto lyophilized powder.

3. Gently rotate the vial to dissolve powder. DO NOT shake violently to avoid peptide aggregation and degradation. Qualified solution is clear and colourless.
4. Storage Requirements

• Unreconstituted lyophilized powder: Hermetically sealed, stored at -20°C, protected from light. Stable for up to 24 months.
• Reconstituted peptide solution: Refrigerate 2°C ~ 8°C, stable within 28 days. Do not freeze reconstituted liquid.

5. Research Administration Protocols

Primary Route: Subcutaneous Injection

Reference Experimental Dosage (Extrapolated from preclinical models)

• Loading experimental phase: 400–750 mcg, 2–3 times weekly for 2–3 weeks
• Maintenance experimental phase: 200–400 mcg, 1–2 times weekly after visible tissue recovery response
• Injection site: Abdomen, thigh or around localized injury sites; rotate injection positions regularly.

Reference Experimental Cycle

Continuous research administration for maximum 6–8 weeks, pause at least 4 weeks before starting a new experimental cycle.

6. Precautions & Observed Adverse Reactions

1. Pure laboratory research compound. Not authorized for human therapeutic use.
2. Strict aseptic technique required during reconstitution to prevent microbial contamination.
3. Discard solution immediately if turbidity, precipitation or discoloration appears.
4. Common mild observed effects: slight redness, itching or tenderness at injection site. Systemic adverse reactions are rare within standard experimental doses.
5. Limited long-term high-dose safety data available. Avoid prolonged continuous exposure.
6. Do not confuse Fragment 17-23 with full-length Thymosin Beta-4; biological activity spectrum and pharmacokinetics are not identical.

Short Version (For Product Page / Customer Direct Message)

Thymosin Beta-4 Fragment 17-23 (TB-500)

Thymosin Beta-4 Fragment 17-23 is a synthetic acetylated heptapeptide containing the core actin-binding domain of endogenous Thymosin Beta-4. It regulates actin dynamics, accelerates cell migration and angiogenesis, and is widely used for wound healing, tendon/muscle injury regeneration and anti-scarring laboratory research.

Reconstitution

Mix lyophilized powder with bacteriostatic water. Rotate gently; avoid violent shaking. Reconstituted solution must be refrigerated and used within 28 days.

Reference Subcutaneous Research Dosage

200–750 mcg per injection, 1–3 times weekly. Loading phase is recommended for acute injury research models.